Ranbaxy to strengthen US business
Ranbaxy Laboratories, the country's biggest drug maker, is all set to strengthen its business in the US despite an import restriction on 30 of its medicines by the US Food and Drugs Authority.
"Ranbaxy will increase its share of business in the US soon. We are responding to all queries from US FDA and will emerge as a stronger player in the world's biggest pharmaceutical market," Ranbaxy Chairman and Managing Director Malvinder Singh said. US sales account for 20 per cent of Ranbaxy’s $1.5-billion annual turnover.
Speaking to reporters on the sidelines of the third India-Brazil-South Africa Business Meet here today, Singh said the company is confident of the quality and efficacy of its products in the US. The company is making alternative arrangements to ensure that all products, including the ones for which the company has limited market exclusivity, are launched in the US market without any delay, Singh added.
The company, which is in the process of being taken over by Japan’s Daiichi Sankyo for $4.6 billion, expects to close the deal in the coming months. "The share transaction should be completed before December," Singh said. According to Singh, the post-transaction days will find Ranbaxy making strategic investments to strengthen its overseas business, including the US. The company has been facing severe regulatory scrutiny in the US after FDA allegedly found technical problems with the documentation processes and systems followed by the company in two of its Indian manufacturing units.
The US FDA had even filed an information seeking motion against Ranbaxy in a US district court. The motion was withdrawn recently after the company submitted all data sought by the US FDA.
October 16, 2008